Leerink cuts BMY target to $59 on downgrade
Alpha Vantage · www.marketscreener.com · · AI-summarised by FinFlash
Leerink Partners has downgraded Bristol-Myers Squibb (BMY) from Outperform to Market Perform and lowered its price target from $73 to $59. This analyst action reflects a less optimistic outlook on the pharmaceutical company's future performance. The article also provides recent news headlines related to Bristol-Myers Squibb, including FDA approvals and strategic partnerships.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.